Reyataz — Competitive Intelligence Brief

Reyataz (ATAZANAVIR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease Inhibitor. Area: Immunology.

marketed Protease Inhibitor UDP-glucuronosyltransferase 1-1 Immunology Small molecule

Target snapshot

Reyataz (ATAZANAVIR) — Bristol-Myers Squibb. Reyataz works by blocking the protease enzyme, which is essential for the replication of HIV.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Reyataz TARGET	ATAZANAVIR	Bristol-Myers Squibb	marketed	Protease Inhibitor	UDP-glucuronosyltransferase 1-1	2003-01-01
Norvir	Norvir	Saint Michael's Medical Center	marketed		UDP-glucuronosyltransferase 1-1, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1
PF-07321332 Dose 5	pf-07321332-dose-5	Pfizer	marketed	Protease inhibitor	Main protease (MPro) of SARS-CoV-2	Pending regulatory approval
Paxlovid (Copackaged)	Nirmatrelvir	Pfizer	marketed	Antiviral protease inhibitor	SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease)	2023-01-01
Victrelis	BOCEPREVIR	Merck & Co.	marketed	Hepatitis C Virus NS3/4A Protease Inhibitor	Chymase	2011-01-01
Prezista	DARUNAVIR	Janssen Prods	marketed	Protease Inhibitor [EPC]	Multidrug resistance protein 1	2006-01-01
TIPRANAVIR	TIPRANAVIR		marketed	Protease Inhibitor [EPC]		2005-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2041-08-05 — Paxlovid (Copackaged) · 11351149 · US
• 2041-10-31 — Paxlovid (Copackaged) · 11541034 · US

Sponsor landscape (Protease Inhibitor class)

1. GSK · 2 drugs in this class
2. Agouron Pharms · 1 drug in this class
3. Bristol-Myers Squibb · 1 drug in this class